Towards Healthcare Research & Consulting

Cerenome Launches CNSide® CSF Molecular Profile Tests

Category: Health Published Date: 16 October 2026
Share : Healthcare Services Healthcare Services Healthcare Services Healthcare Services Healthcare Services

CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc., commercially rolled out two innovative cerebrospinal fluid (CSF)-based molecular profiling tests & made them available to health care professionals across the United States from October 12, 2026. This primarily covers:

  • CNSide® CSF Molecular Profile - Solid Tumor (DNA & RNA)
  • CNSide® CSF Molecular Profile - Hematologic Malignancies (DNA & RNA)

Particularly designed, CNSide CSF Molecular Profile widely offer extensive DNA and RNA profiling of CNS disease biology from cerebrospinal fluid. This test pushes the analysis of more than 300 cancer-related genes in cell-free DNA and more than 1,600 transcripts by RNA sequencing & enables expansive characterization of genomic and transcriptomic alterations, like sequence variants, copy-number alterations, and gene fusions. Moreover, the Hematologic Malignancies test also fosters molecular study of clonality.

The respective launch of tests drastically elevates the patient population, which can be facilitated by CNSide. At the same time, CNSide® CSF Tumor Cell Enumeration (TCE) is expanding its emphasis on patients with suspected or confirmed leptomeningeal metastases, whereas Molecular Profile broadens CSF-based molecular testing to primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies comprising the CNS.

"Physicians managing cancer in the CNS need more than confirmation that disease is present. They need information they can act on," said Russell Bradley, President and General Manager of CNSide Diagnostics, LLC. "Molecular Profile adds DNA and RNA findings, including potentially actionable alterations, to the cellular information CNSide already provides, and extends CNSide beyond leptomeningeal metastases to primary CNS tumors and hematologic cancers involving the CNS."

Moreover, with a focus on patients with leptomeningeal metastases, Molecular Profile can be ordered solely or along with TCE as both cellular and molecular evaluation are clinically adequate. In addition, TCE supports determining and quantitatively enumerating tumor cells, meanwhile Molecular Profile spurs characterization of the DNA and RNA biology of disease & finally gives complementary cellular and molecular information from the same CSF collection.

A specific solution with basic CNSide CSF Molecular Profile was recently studied in a peer-reviewed, real-world assessment by Albitar et al., investigators at Genomic Testing Cooperative (GTC) and published in The Journal of Liquid Biopsy. However, this evaluation examined 1,391 evaluable CSF specimens from patients being assessed for primary CNS tumors, metastatic CNS disease, and hematologic malignancies entailing the CNS. Moreover, cancer-related molecular conclusions were found in 78.4% of evaluable specimens. Besides this, the study uncovered several categories of molecular abnormalities, such as sequence variants, copy-number and chromosomal alterations, gene fusions, and clonality. 

Briefing on Uncovered Entities

Furthermore, the emergence of the CNSide CSF Molecular Profile is provided via an alliance between CNSide Diagnostics & GTC in July 2026. An eminent GTC runs the DNA and RNA sequencing and bioinformatics analysis, while CNSide Diagnostics handles test ordering, results delivery, physician support and billing.

A successful unveiling was built on CNSide's well-nurtured experience in CSF-based oncology diagnostics. Since 2020, >11,000 CNSide tests have been conducted at more than 120 U.S. cancer institutions. The overall clinical use of CNSide CSF tumor-cell study in leptomeningeal metastases has been evaluated in 12 peer-reviewed publications, upcoming multicenter evidence from the FORESEE clinical study, and real-world clinical experience. 

About CNSide Diagnostics, LLC

This is a wholly owned subsidiary of Cerenome, Inc., which steps towards the development and commercialization of cerebrospinal fluid-based diagnostic tests for cancers of the central nervous system. Moreover, the CNSide® CSF diagnostics platform integrates cellular analysis, biomarker characterization, and molecular profiling to offer the detection, characterization, and longitudinal assessment of CNS malignancies.

In this era, the firm has been providing CNSide® CSF Tumor Cell Enumeration for patients with suspected or confirmed leptomeningeal metastases, while CNSide® CSF Molecular Profile tests for molecular characterization of primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS.

About Cerenome

Cerenome is a major CNS oncology player that advances a unified platform via integrating precision diagnostics, targeted therapeutics, and artificial intelligence to enhance results for patients with central nervous system cancers. Moreover, the Company's CNSide® Diagnostics platform assists in the determination, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing.

The firm, with its key therapeutic platform called REYOBIQ™ (rhenium Re186 obisbemeda), is being analyzed in clinical trials, especially for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. Additionally, the data & AI platform is established to pair diagnostic, molecular, imaging, and clinical data into actionable insights for spurring precision oncology and therapeutic innovation. Upon the integration of commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and AI within a single organization, Cerenome is developing a distinct CNS oncology platform that optimizes patient care & creates long-term shareholder value.

Forward-Looking Statements

According to the press release, certain statements may be deemed "forward-looking statements" within the meaning of U.S. securities laws, such as statements about clinical trials, projected operations and prospective developments. Thus, all statements in this press release other than statements of historical fact are forward-looking statements. These statements may be found by future verbs, alongside terms like "expect," "potential," "anticipating," "planning" and similar expressions or the negatives thereof.

These kinds of statements mainly rely on some assumptions and evaluations done by management in focus of their experience and their observation of historical trends, current conditions, anticipated upcoming developments and other aspects they considered to be proper.

Furthermore, these statements cover, regardless of limitation, related to the timing of availability of CNSide CSF Molecular Profile tests; its predicted turnaround time, performance and clinical utility; physician adoption and ordering patterns; the timing and content of additional CNSide menu tests; coverage, billing and reimbursement for CNSide CSF Molecular Profile and other CNSide tests. Moreover, the firm is depending on third-party laboratory service providers, specifically for the CNSide tests, while the timing in which CNSide tests are commercially introduced, with broadened commercialization. And finally, the entire execution emphasizes the development and utility of CNSide tests, along with anticipations as to the Company's prospective performance, such as the next steps in emerging the Company's product entities.

Source- https://www.globenewswire.com/news-release/2026/10/06/3375350/0/en/cerenome-launches-cnside-csf-molecular-profile-tests.html